Should I buy Thermo Fisher Scientific (TMO) stock or is it too late?

Thermo Fisher Scientific · Health Care · price $631
Logo Thermo Fisher ScientificSee the full Thermo Fisher Scientific (TMO) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley69% of its targets hit on this sector (825 calls tested). It aims for $650 (+3.1 %), call made on July 28, 2026, maturing on July 28, 2027 (31 d ago).

The 3 reliable analysts $650+3.1 %
The 6 other firms $590-6.5 %
How to read it: the 3 reliable firms are not filtered by optimism — 2 aim above the price, 1 below, hence their $650 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Thermo Fisher Scientific

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
UBS91 %+29.7 %11$590 -6%
Citigroup71 %+20.7 %17$685 +9%
Argus Research86 %+18.8 %7$610 -3%
BTIG67 %+14.0 %9$718 +14%
Stifel73 %+13.7 %15$600 -5%
Morgan Stanley76 %+13.6 %25$650 +3%
Baird70 %+12.8 %30$639 +1%
Barclays58 %+9.9 %24$650 +3%
In short — Should you invest in Thermo Fisher Scientific? Is it too late, still worth it? Analysts are fairly positive (67% buy, median target $600, i.e. -5%). But the valuation is stretched (P/E ~34), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 67% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.

⚠️ Reasons to hesitate

  • Even the most reliable firm on TMO, UBS (91% hit rate, 11 scored calls), only targets $590 (call made on October 23, 2025, maturing on October 23, 2026) (-6%) in its most recent call. The stock may already have run past its target.
  • The consensus is not unanimous: of 9 ratings, 3 are neutral.
  • Limited upside: the median target is only -5% from the current price.
  • High valuation (P/E ~34): strong growth is already "priced in", leaving little room for error.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • Negligible dividend (0.3% yield): your return depends mostly on price appreciation.

The analyst consensus on TMO

Median target $600 (-5%) · 9 ratings · Buy consensus

Strong Buy00%
Buy667%
Hold333%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Thermo Fisher Scientific now?

We won't decide for you. The facts: 67% of analysts rate it a buy, median target $600 (-5%), and UBS (most reliable on TMO, 91%) targets $590. Weigh that against valuation (P/E ~34). This is not personalized advice.

Is it too late to invest in Thermo Fisher Scientific?

The stated upside is small: the median target ($600) sits just -5% from the price ($631) (most reliable on TMO: UBS, 91%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Thermo Fisher Scientific still worth investing in?

It depends on the gap between the price ($631) and its estimated value: analysts target $600 on median (-5%), with 67% buys (most reliable on TMO: UBS, 91%). Cross-check with their real reliability on TMO and the cautions above. Information, not advice.

What's the main risk in buying TMO?

Even the most reliable firm on TMO, UBS (91% hit rate, 11 scored calls), only targets $590 (call made on October 23, 2025, maturing on October 23, 2026) (-6%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Thermo Fisher Scientific profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)